Prostaglandins and Other Lipid Mediators in Reproductive Medicine

Yen & Jaffe's Reproductive Endocrinology

Volumn , Issue , 2009, Pages 121-137

  Funk, Colin D ^a   Song, Wen Chao ^b   FitzGerald, Garret A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865749767     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4907-4.00006-1     Document Type: Chapter

References (200)

1. von Euler U.S. History and development of prostaglandins. Gen Pharmacol 1983, 14:3-6.
2. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
3. Oates J.A. The 1982 Nobel Prize in Physiology or Medicine. Science 1982, 218:765-768.
4. Arici A., Keefe D.L., Behrman H.R. Prostaglandins and prostaglandin-like products in reproduction: eicosanoids, peroxides, and oxygen radicals. Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management 1999,, 134-152. WB Saunders, Philadelphia. ed 4. S.C. Samuel, R.B.J. Yen, R.L. Barbieri (Eds.).
5. Brash A.R. Arachidonic acid as a bioactive molecule. J Clin Invest 2001, 107:1339-1345.
6. Fitzpatrick F.A., Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001, 107:1347-1351.
7. Six D.A., Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000, 1488:1-19.
8. Murakami M., Kambe T., Shimbara S., et al. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 1999, 274:3103-3115.
9. Tanioka T., Nakatani Y., Semmyo N., et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000, 275:32775-32782.
10. Murakami M., Naraba H., Tanioka T., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
11. Cho Y.Y., Kang M.J., Sone H., et al. Abnormal uterus with polycysts, accumulation of uterine prostaglandins, and reduced fertility in mice heterozygous for acyl-CoA synthetase 4 deficiency. Biochem Biophys Res Commun 2001, 284:993-997.
12. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
13. Smith W. Molecular biology of prostanoid biosynthetic enzymes and receptors. Adv Exp Med Biol 1997, 989-1011.
14. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999, 274:23679-23682.
15. Chen X.S., Sheller J.R., Johnson E.N., et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994, 372:179-182.
16. Schwab J.M., Serhan C.N. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006, 6:414-420.
17. Capdevila J.H., Falck J.R., Harris R.C. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000, 41:163-181.
18. Holla V.R., Makita K., Zaphiropoulos P.G., et al. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999, 104:751-760.
19. Holla V.R., Adas F., Imig J.D., et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A 2001, 98:5211-5216.
20. Catella F., Lawson J.A., Fitzgerald D.J., et al. Endogenous biosynthesisof arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A 1990, 87:5893-5897.
21. Node K., Huo Y., Ruan X., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
22. Roberts LJ II, Morrow J.D. Isoprostanes: novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann N Y Acad Sci 1994, 744:237-242.
23. Pratico D., Lawson J.A., Rokach J., et al. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001, 12:243-247.
24. Morrow J.D., Awad J.A., Boss H.J., et al. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A 1992, 89:10721-10725.
25. Kunapuli P., Lawson J.A., Rokach J.A., et al. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III,induce cardiomyocyte hypertrophy: differential activation of downstream signaling pathways. J Biol Chem 1998, 273:22442-22452.
26. Davi G., Guagnano M.T., Ciabattoni G., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288:2008-2014.
27. Meagher E.A., Barry O.P., Burke A., et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999, 104:805-813.
28. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107:1491-1495.
29. Harris R.C., McKanna J.A., Akai Y., et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504-2510.
30. Jakobsson P.J., Thoren S., Morgenstern R., et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999, 96:7220-7225.
31. Parent J., Fortier M.A. Expression and contribution of three different isoforms of prostaglandin E synthase in the bovine endometrium. Biol Reprod 2005, 73:36-44.
32. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001, 14:611-650.
33. Narumiya S., Ohno K., Fukushima M., et al. Site and mechanism of growth inhibition by prostaglandins: distribution and binding of prostaglandin A2 and delta 12-prostaglandin J2 in nuclei. J Pharmacol Exp Ther 1987, 242:306-311.
34. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220:568-575.
35. Peters-Golden M., McNish R.W. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun. 1993, 196:147-153.
36. Chen X.S., Funk C.D. The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem 2001, 276:811-818.
37. Dixon R.A., Diehl R.E., Opas E., et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343:282-284.
38. Funk C.D., Radmark O., Fu J.Y., et al. Molecular cloning and amino acid sequence of leukotriene A4 hydrolase. Proc Natl Acad Sci U S A 1987, 84:6677-6681.
39. Penrose J.F., Austen K.F. The biochemical, molecular, and genomic aspects of leukotriene C4 synthase. Proc Assoc Am Physicians 1999, 111:537-546.
40. Folco G., Murphy R.C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006, 58:375-388.
41. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999, 103:1597-1604.
42. Cyrus T., Pratico D., Zhao L., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001, 103:2277-2282.
43. Zhao L., Cuff C.A., Moss E., et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 2002, 16:35350-35356.
44. Schuster V.L. Molecular mechanisms of prostaglandin transport. Annu Rev Physiol 1998, 60:221-242.
45. Reid G., Wielinga P., Zelcer N., et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003, 100:9244-9249.
46. Cole S.P., Deeley R.G. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006, 27:438-446.
47. Ensor C.M., Yang J.Y., Okita R.T., et al. Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J Biol Chem 1990, 265:14888-14891.
48. Lee S.C., Levine L. Purification and properties of chicken heart prostaglandin delta13-reductase. Biochem Biophys Res Commun 1974, 61:14-21.
49. FitzGerald G.A., Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001, 107:1335-1337.
50. Masferrer J.L., Isakson P.C., Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996, 25:363-372.
51. Chen W., Pawelek T.R., Kulmacz R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J Biol Chem 1999, 274:20301-20306.
52. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442.
53. Grosser T., Yusuff S., Cheskis E., et al. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A 2002, 99:8418-8423.
54. Langenbach R., Morham S.G., Tiano H.F., et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995, 83:483-492.
55. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482.
56. Dinchuk J.E., Car B.D., Focht R.J., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409.
57. Lim H., Paria B.C., Das S.K., et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997, 91:197-208.
58. McAdam B.F., Catella-Lawson F., Mardini I.A., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272-277.
59. Sugimoto Y., Narumiya S., Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000, 39:289-314.
60. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25-30.
61. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
62. Hirata M., Hayashi Y., Ushikubi F., et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991, 349:617-620.
63. Narumiya S. Molecular diversity of prostanoid receptors: subtypes and isoforms of prostaglandin E receptor. Adv Exp Med Biol 1997, 207-213.
64. Pierce K.L., Bailey T.J., Hoyer P.B., et al. Cloning of a carboxyl-terminalisoform of the prostanoid FP receptor. J Biol Chem 1997, 272:883-887.
65. Raychowdhury M.K., Yukawa M., Collins L.J., et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994, 269:19256-19261.
66. Hirai H., Tanaka K., Yoshie O., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193:255-261.
67. Monneret G., Gravel S., Diamond M., et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001, 98:1942-1948.
68. Monneret G., Li H., Vasilescu J., et al. 15-Deoxy-delta 12, 14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol 2002, 168:3563-3569.
69. Smyth E.M., Austin S.C., Reilly M.P., et al. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000, 275:32037-32045.
70. Yokomizo T., Izumi T., Chang K., et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
71. Yokomizo T., Kato K., Terawaki K., et al. A second leukotriene B(4) receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000, 192:421-432.
72. Labat C., Ortiz J.L., Norel X., et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992, 263:800-805.
73. Lynch K.R., O'Neill G.P., Liu Q., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999, 399:789-793.
74. Heise C.E., O'Dowd B.F., Figueroa D.J., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000, 275:30531-30536.
75. Ciana P., Fumagalli M., Trincavelli M.L., et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006, 25:4615-4627.
76. Lim H., Dey S.K. Minireview: a novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002, 143:3207-3210.
77. Yu K., Bayona W., Kallen C.B., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983.
78. Forman B.M., Tontonoz P., Chen J., et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
79. Kliewer S.A., Lenhard J.M., Willson T.M., et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
80. Devchand P.R., Keller H., Peters J.M., et al. The PPARalpha-leukotrieneB4 pathway to inflammation control. Nature 1996, 384:39-43.
81. Gupta R.A., Tan J., Krause W.F., et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 2000, 97:13275-13280.
82. Hatae T., Wada M., Yokoyama C., et al. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001, 276:46260-46267.
83. Lim H., Gupta R.A., Ma W.G., et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999, 13:1561-1574.
84. Zikopoulos K.A., Papanikolaou E.G., Kalantaridou S.N., et al. Early pregnancy termination with vaginal misoprostol before and after 42 days gestation. Hum Reprod 2002, 17:3079-3083.
85. Bartley J., Baird D.T. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002, 109:1290-1294.
86. Mendilcioglu I., Simsek M., Seker P.E., et al. Misoprostol in second and early third trimester for termination of pregnancies with fetal anomalies. Int J Gynaecol Obstet 2002, 79:131-135.
87. Murdoch W.J., Hansen T.R., McPherson L.A. A review: role of eicosanoids in vertebrate ovulation. Prostaglandins 1993, 46:85-115.
88. McCracken J.A., Carlson J.C., Glew M.E., et al. Prostaglandin F2 identified as a luteolytic hormone in sheep. Nat New Biol 1972, 238:129-134.
89. Moeljono M.P., Bazer F.W., Thatcher W.W. A study of prostaglandin F2alpha as the luteolysin in swine: I. Effect of prostaglandin F2alpha in hysterectomized gilts. Prostaglandins 1976, 11:737-743.
90. Heymann M.A., Rudolph A.M., Silverman N.H. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976, 295:530-533.
91. Mielke G., Gonser M. Closure of the human fetal ductus arteriosus. Am J Obstet Gynecol 1997, 176:495-496.
92. Harms P.G., Ojeda S.R., McCann S.M. Prostaglandin involvement in hypothalamic control of gonadotropin and prolactin release. Science 1973, 181:760-761.
93. Ojeda S.R., Naor Z., McCann S.M. Prostaglandin E levels in hypothalamus, median eminence and anterior pituitary of rats of both sexes. Brain Res 1978, 149:274-277.
94. Wetsel W.C. Immortalized hypothalamic luteinizing hormone-releasing hormone (LHRH) neurons: a new tool for dissecting the molecular and cellular basis of LHRH physiology. Cell Mol Neurobiol 1995, 15:43-78.
95. Franchi A., Gimeno M., Szwarcfarb B., et al. Changes in the hypothalamic interaction between norepinephrine and prostaglandin E2 during sexual maturation in female rats. Neuroendocrinology 1995, 62:226-230.
96. Davis B.J., Lennard D.E., Lee C.A., et al. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-lbeta. Endocrinology 1999, 140:2685-2695.
97. Hedin L., Gaddy-Kurten D., Kurten R., et al. Prostaglandin endoperoxide synthase in rat ovarian follicles: content, cellular distribution, and evidence for hormonal induction preceding ovulation. Endocrinology 1987, 121:722-731.
98. Wong W.Y., DeWitt D.L., Smith W.L., et al. Rapid induction of prostaglandin endoperoxide synthase in rat preovulatory follicles by luteinizing hormone and cAMP is blocked by inhibitors of transcription and translation. Mol Endocrinol 1989, 3:1714-1723.
99. Wong W.Y., Richards J.S. Evidence for two antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary. Mol Endocrinol 1991, 5:1269-1279.
100. Sirois J., Levy L.O., Simmons D.L., et al. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells: identification of functional and protein-binding regions. J Biol Chem 1993, 268:12199-12206.
101. Sirois J., Dore M. The late induction of prostaglandin G/H synthase-2 in equine preovulatory follicles supports its role as a determinant of the ovulatory process. Endocrinology 1997, 138:4427-4434.
102. Duffy D.M., Stouffer R.L. The ovulatory gonadotrophin surge stimulates cyclooxygenase expression and prostaglandin production by the monkey follicle. Mol Hum Reprod 2001, 7:731-739.
103. Duffy D.M., Stouffer R.L. Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys. Hum Reprod 2002, 17:2825-2831.
104. Richards J.S. Sounding the alarm: does induction of prostaglandin endoperoxide synthase-2 control the mammalian ovulatory clock?. Endocrinology 1997, 138:4047-4048.
105. Richards J.S., Russell D.L., Ochsner S., et al. Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 2002, 64:69-92.
106. Reese J., Zhao X., Ma W.G., et al. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 2001, 142:3198-3206.
107. Mikuni M., Pall M., Peterson C.M., et al. The selective prostaglandin endoperoxide synthase-2 inhibitor, NS-398, reduces prostaglandin production and ovulation in vivo and in vitro in the rat. Biol Reprod 1998, 59:1077-1083.
108. Pall M., Friden B.E., Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001, 16:1323-1328.
109. Stone S., Khamashta M.A., Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link?. Drug Saf 2002, 25:545-551.
110. Sugimoto Y., Yamasaki A., Segi E., et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997, 277:681-683.
111. Kennedy C.R., Zhang Y., Brandon S., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999, 5:217-220.
112. Hizaki H., Segi E., Sugimoto Y., et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci U S A 1999, 96:10501-10506.
113. Matsumoto H., Ma W., Smalley W., et al. Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation. Biol Reprod 2001, 64:1557-1565.
114. Sugimoto Y., Hasumoto K., Namba T., et al. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem 1994, 269:1356-1360.
115. Powell W.S., Hammarström S., Samuelsson B., et al. Letter: prostaglandin-F2alpha receptor in human corpora lutea. Lancet 1974, 1:1120.
116. Bennegard B., Hahlin M., Wennberg E., et al. Local luteolytic effect of prostaglandin F2 alpha in the human corpus luteum. Fertil Steril 1991, 56:1070-1076.
117. Manaugh L.C., Novy M.J. Effects of indomethacin on corpus luteum function and pregnancy in rhesus monkeys. Fertil Steril 1976, 27:588-598.
118. Sargent E.L., Baughman W.L., Novy M.J., et al. Intraluteal infusion of a prostaglandin synthesis inhibitor, sodium meclofenamate, causes premature luteolysis in rhesus monkeys. Endocrinology 1988, 123:2261-2269.
119. McCracken J.A., Custer E.E., Lamsa J.C. Luteolysis: a neuroendocrine-mediated event. Physiol Rev 1999, 79:263-323.
120. Cheng J.G., Stewart C.L. Loss of cyclooxygenase-2 retards decidual growth but does not inhibit embryo implantation or development to term. Biol Reprod 2002, 68:401-404.
121. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997, 94:4312-4317.
122. Murata T., Ushikubi F., Matsuoka T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
123. Huang J.C., Wun W.S., Goldsby J.S., et al. Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVF. Hum Reprod 2007, 22:807-814.
124. Barak Y., Liao D., He W., et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:303-308.
125. Huang J.C., Wun W.S., Goldsby J.S., et al. Prostacyclin receptor signaling and early embryo development in the mouse. Hum Reprod 2007, 22:2851-2856.
126. Koike H., Egawa H., Ohtsuka T., et al. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. Prostaglandins Leukot Essent Fatty Acids 1992, 46:133-137.
127. Dawood M.Y. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med 1988, 84:23-29.
128. Hayes E.C., Rock J.A. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002, 57:768-780.
129. Daniels S.E., Talwalker S., Torri S., et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002, 100:350-358.
130. Lewis R.B., Schulman J.D. Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour. Lancet 1973, 2:1159-1161.
131. Skarnes R.C., Harper M.J. Relationship between endotoxin-induced abortion and the synthesis of prostaglandin F. Prostaglandins 1972, 1:191-203.
132. Fidel P.L., Romero R., Wolf N., et al. Systemic and local cytokine profiles in endotoxin-induced preterm parturition in mice. Am J Obstet Gynecol 1994, 170:1467-1475.
133. Kelly R.W. Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response. Endocr Rev 1994, 15:684-706.
134. Gross G.A., Imamura T., Luedke C., et al. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc Natl Acad Sci U S A 1998, 95:11875-11879.
135. Yu Y., Cheng Y., Fan J., et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 2005, 115:986-995.
136. Reese J., Paria B.C., Brown N., et al. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A 2000, 97:9759-9764.
137. Cook J.L., Shallow M.C., Zaragoza D.B., et al. Mouse placental prostaglandins are associated with uterine activation and the timing of birth. Biol Reprod 2002, 68:579-587.
138. Winchester S.K., Imamura T., Gross G.A., et al. Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 2002, 143:2593-2598.
139. Ellwood D.A., Mitchell M.D., Anderson A.B., et al. The in vitro production of prostanoids by the human cervix during pregnancy: preliminary observations. Br J Obstet Gynaecol 1980, 87:210-214.
140. Rayburn W.F. Preinduction cervical ripening: basis and methods of current practice. Obstet Gynecol Surv 2002, 57:683-692.
141. Gross G., Imamura T., Vogt S.K., et al. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. Am J Physiol Regul Integr Comp Physiol(IP) 2000, 278:1415-1423.
142. Morales W.J., Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993, 169:97-102.
143. Abramov Y., Nadjari M., Weinstein D., et al. Indomethacin for preterm labor: a randomized comparison of vaginal and rectal-oral routes. Obstet Gynecol 2000, 95:482-486.
144. Vermillion S.T., Landen C.N. Prostaglandin inhibitors as tocolytic agents. Semin Perinatol 2001, 25:256-262.
145. Loftin C.D., Trivedi D.B., Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest 2002, 110:549-557.
146. Sakai M., Tanebe K., Sasaki Y., et al. Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol Hum Reprod 2001, 7:595-602.
147. Takahashi Y., Roman C., Chemtob S., et al. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1496-R1505.
148. Stika C.S., Gross G.A., Leguizamon G., et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol 2002, 187:653-660.
149. Smith G.C. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998, 50:35-58.
150. Loftin C.D., Trivedi D.B., Tiano H.F., et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1and cyclooxygenase-2. Proc Natl Acad Sci U S A 2001, 98:1059-1064.
151. Segi E., Sugimoto Y., Yamasaki A., et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998, 246:7-12.
152. Nguyen M., Camenisch T., Snouwaert J.N., et al. The prostaglandin receptor EP4 triggers remodeling of the cardiovascular system at birth. Nature 1997, 390:78-81.
153. Coggins K.G., Latour A., Nguyen M.S., et al. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002, 8:91-92.
154. Yokoyama U., Minamisawa S., Quan H., et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 2006, 116:3026-3034.
155. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol 1988, 71:122-137.
156. Fitzgerald D.J., Entman S.S., Mulloy K., et al. Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 1987, 75:956-963.
157. Fitzgerald D.J., Mayo G., Catella F., et al. Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. Am J Obstet Gynecol 1987, 157:325-330.
158. Fitzgerald D.J., Rocki W., Murray R., et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990, 335:751-754.
159. Rocca B., Loeb A.L., Strauss J.F., et al. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 2000, 6:219-221.
160. Wallenburg H.C. Prevention of pre-eclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol 2001, 94:13-22.
161. Duley L., Henderson-Smart D., Knight M., et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001, 322:329-333.
162. Caritis S., Sibai B., Hauth J., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998, 338:701-705.
163. Mills J.L., DerSimonian R., Raymond E., et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999, 282:356-362.
164. Hauth J., Sibai B., Caritis S., et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. Am J Obstet Gynecol 1998, 179:1193-1199.
165. McKanna J.A., Zhang M.Z., Wang J.L., et al. Constitutive expression of cyclooxygenase-2 in rat vas deferens. Am J Physiol 1998, 275:R227-R233.
166. Cheuk B.L., Leung P.S., Lo A.C., et al. Androgen control of cyclooxygenase expression in the rat epididymis. Biol Reprod 2000, 63:775-780.
167. Kirschenbaum A., Liotta D.R., Yao S., et al. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 2000, 85:3436-3441.
168. Sorrentino C., Silvestrini B., Braghiroli L., et al. Rat prostaglandin D2 synthetase: its tissue distribution, changes during maturation, and regulation in the testis and epididymis. Biol Reprod 1998, 59:843-853.
169. Lazarus M., Munday C.J., Eguchi N., et al. Immunohistochemical localization of microsomal PGE synthase-1 and cyclooxygenases in male mouse reproductive organs. Endocrinology 2002, 143:2410-2419.
170. Walch L., Morris P.L. Cyclooxygenase 2 pathway mediates IL-1beta regulation of IL-1alpha, -Ibeta, and IL-6 mRNA levels in Leydig cell progenitors. Endocrinology 2002, 143:3276-3283.
171. Cheuk B.L., Chew S.B., Fiscus R.R., et al. Cyclooxygenase-2 regulates apoptosis in rat epididymis through prostaglandin D2. Biol Reprod 2002, 66:374-380.
172. Wespes E., Sattar A.A., Noel J.C., et al. Does prostaglandin E1 therapy modify the intracavernous musculature?. J Urol 2000, 163:464-466.
173. Khan M.A., Thompson C.S., Sullivan M.E., et al. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostaglandins Leukot Essent Fatty Acids 1999, 60:169-174.
174. Budnik L.T., Mukhopadhyay A.K. Lysophosphatidic acid and its role in reproduction. Biol Reprod 2002, 66:859-865.
175. Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004, 15:477-489.
176. Lee C.W., Rivera R., Gardell S., et al. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006, 281:23589-23597.
177. Hla T., Lee M.J., Ancellin N., et al. Lysophospholipids: receptor revelations. Science 2001, 294:1875-1878.
178. Zhang H., Desai N.N., Olivera A., et al. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991, 114:155-167.
179. Sadahira Y., Ruan F., Hakomori S., et al. Sphingosine 1-phosphate, a specific endogenous signaling molecule controlling cell motility and tumor cell invasiveness. Proc Natl Acad Sci U S A 1992, 89:9686-9690.
180. Sanchez T., Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004, 92:913-922.
181. Tokumura A., Fukuzawa K., Yamada S., et al. Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregnant rats. Arch Int Pharmacodyn Ther 1980, 245:74-83.
182. Ye X., Hama K., Contos J.J., et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435:104-108.
183. Hama K., Aoki J., Bandoh K., et al. Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci 2006, 79:1736-1740.
184. Kennedy T.G. Evidence for a role for prostaglandins in the initiation of blastocyst implantation in the rat. Biol Reprod 1977, 16:286-291.
185. Kinoshita K., Satoh K., Ishihara O., et al. Involvement of prostaglandins in implantation in the pregnant mouse. Adv Prostaglandin Thromboxane Leukot Res 1985, 15:605-607.
186. Song H., Lim H., Paria B.C., et al. Cytosolic phospholipase A2alpha is crucial [correction of A2alpha deficiency is crucial] for 'on-time' embryo implantation that directs subsequent development. Development 2002, 129(12). 2879-2789 Erratum in: Development 129(15):3761, 2002.
187. Skaznik-Wikiel M.E., Kaneko-Tarui T., Kashiwagi A., et al. Sphingosine-1-phosphate receptor expression and signaling correlate with uterine prostaglandin-endoperoxide synthase 2 expression and angiogenesis during early pregnancy. Biol Reprod 2006, 74:569-576.
188. Tilly J.L. Commuting the death sentence: how oocytes strive to survive. Nat Rev Mol Cell Biol 2001, 2:838-848.
189. Perez G.I., Jurisicova A., Matikainen T., et al. A central role for ceramide in the age-related acceleration of apoptosis in the female germline. FASEB J 2005, 19:860-862.
190. Suomalainen L., Hakala J.K., Pentikainen V., et al. Sphingosine-1-phosphate in inhibition of male germ cell apoptosis in the human testis. J Clin Endocrinol Metab 2003, 88:5572-5579.
191. Otala M., Pentikainen M.O., Matikainen T., et al. Effects of acid sphingomyelinase deficiency on male germ cell development and programmed cell death. Biol Reprod 2005, 72:86-96.
192. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
193. Gross G.A., Imamura T., Luedke C., et al. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc Natl Acad Sci U S A 1998, 95:11875-11879.
194. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of
195. Reese J., Paria B.C., Brown N., et al. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A 2000, 97:9759-9764.
196. Reese J., Zhao X., Ma W.G., et al. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 2001, 142:3198-3206.
197. Richards J.S., Russell D.L., Ochsner S., et al. Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 2002, 64:69-92.
198. Sugimoto Y., Yamasaki A., Segi E., et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997, 277:681-683.
199. Tilly J.L. Commuting the death sentence: how oocytes strive to survive. Nat Rev Mol Cell Biol 2001, 2:838-848.
200. Vermillion S.T., Landen C.N. Prostaglandin inhibitors as tocolytic agents. Semin Perinatol 2001, 25:256-262.